Posted by Michael Wonder on 06 Mar 2026
Roche's Columvi, Takeda's Fruzaqla pass first review for Korea insurance coverage
5 March 2026 - Roche's DLBCL treatment Columvi (glofitamab) and Takeda's metastatic colorectal cancer treatment Fruzaqla (fruquintinib) have cleared the Cancer Disease Review Committee, the first hurdle for insurance coverage.
At the same time, changes to reimbursement criteria for certain targeted therapies were also discussed, affecting treatments for rare genetic mutation–associated renal cell carcinoma and prostate cancer.
